| Bioactivity | Rifaquizinone (CBR-2092) is a Rifamycin-Quinolone Hybrid Antibiotic. Rifaquizinone inhibits wild-type S. aureus RNA polymerase with an IC50 of 34 nM. Rifaquizinone is effective against S. aureus infections, with MICs ranged from 0.008 to 0.5 μg/mL for 300 clinical isolates of staphylococci and streptococci[1][2]. |
| Name | Rifaquizinone |
| CAS | 922717-97-3 |
| Formula | C65H81FN6O15 |
| Molar Mass | 1205.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Robertson GT, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrob Agents Chemother. 2008 Jul;52(7):2313-23. [2]. Robertson GT, et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Antimicrob Agents Chemother. 2008 Jul;52(7):2324-34. |
Rifaquizinone
CAS: 922717-97-3 F: C65H81FN6O15 W: 1205.37
Rifaquizinone (CBR-2092) is a Rifamycin-Quinolone Hybrid Antibiotic. Rifaquizinone inhibits wild-type S. aureus RNA poly
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.